Medicus Pharma partners with Gorlin Syndrome Alliance to expand compassionate access to SKINJECT

Proactive - Interviews for investors

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

4d ago 6:26

MP3•Episode home

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to unveil a new strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the company’s investigational doxorubicin-containing dissolvable microneedle array therapy for basal cell carcinoma. The initiative focuses on patients with Gorlin Syndrome—also known as nevoid basal cell carcinoma syndrome—a rare genetic condition that affects an estimated 1 in 31,000 people worldwide. Individuals diagnosed with the disorder can develop hundreds or even thousands of BCCs throughout their lives, often beginning in childhood. Current treatment approaches frequently involve repeated surgeries and ongoing dermatologic interventions, resulting in significant physical scarring, emotional strain, and financial burden. Dr. Bokhari explained that the partnership with the GSA is designed to jointly pursue an Expanded Access IND Program with the U.S. Food and Drug Administration (FDA). This pathway would enable eligible Gorlin Syndrome patients with multiple, recurrent, or inoperable basal cell carcinomas to obtain supervised treatment with SKINJECT™ outside of traditional clinical trials. In addition to facilitating treatment for those with pressing unmet medical needs, the program will support the collection of real-world safety and tolerability data, which will contribute to future regulatory submissions. It will also enable greater incorporation of patient-centered insights into clinical development and long-term treatment strategies. Medicus Pharma is currently underway with its Phase 2 clinical study, SKNJCT-003, which began enrolling patients in August 2024 across nine U.S. trial sites. The study is a double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating SKINJECT™ as a non-invasive therapeutic option for skin-based BCC using proprietary dissolvable D-MNA . Dr. Bokhari emphasized that the collaboration with the GSA reflects Medicus Pharma’s mission to bring innovative, patient-friendly cancer treatments to those most in need, while advancing SKINJECT™ toward broader clinical and commercial milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

606 episodes

#Trading #Business News #Business #News #Proactive Investors #Gold #Cannabis #Battery Metals #Chief Executive #Biotech #Natural Resources #Bitcoin #Cryptocurrency #Interviews #Investing #Investment Research #Mining #Retail Investment #Technology